Latest Advances in Lung Cancer Research

Study shows telehealth is as effective as in-person visits for palliative care, maintaining quality of life and survival rates while improving access to care for seriously ill patients.

Tagrisso significantly improves survival in patients with unresectable stage III EGFR-mutated lung cancer, offering new hope for a longer life.

Lorbrena, a new drug targeting a key protein in cancer cells, shows promise in extending survival for non-small cell lung cancer patients.

Non-smoking Asian American and Pacific Islander women face higher lung cancer risks, prompting research into genetic and environmental causes and new treatments.

“Ground-glass opacity” on lung CT scans, a hazy sign of potential cancer, is linked to higher survival rates, emphasizing the importance of early detection.

New NCCN guidelines help doctors treat lung cancer more effectively with early detection, personalized treatment plans, and comprehensive supportive care recommendations.

AstraZeneca’s Imfinzi shows promise in treating aggressive small cell lung cancer, potentially offering a new, more effective treatment option for this hard-to-treat disease.

The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki, a new drug for treating HER2-positive unresectable or metastatic breast cancer in adults.

Cancer death rates in the U.S. have dropped 33% since 1991, saving 3.8 million lives, but disparities and challenges in certain cancers remain.

Lung cancer rates are increasing among Asian American women, according to a new study published in the journal Cancer.

Weill Cornell Medicine scientists create a mouse model to study lung cancer’s transformation into deadly SCLC.